Neuromedical Systems v. NeoPath
This article was originally published in The Gray Sheet
United States federal district court in New York refuses to grant a preliminary injunction enjoining NeoPath from manufacturing and selling its AutoPap 300 QC system, Neuromedical Systems announces in a May 27 release. The court orders the parties to complete the discovery phase of the suit and return for a pretrial conference by the end of August, NSI adds. The company filed suit in July 1996, alleging that NeoPath "willfully misappropriated" NSI's Papnet automated cervical cytology reader technology and used the technology in the NeoPath AutoPap 300 QC ("The Gray Sheet" July 22, 1996, In Brief). NeoPath later filed suit in March 1997 in the U.S. District Court in Seattle claiming that NSI infringes three NeoPath patents ("The Gray Sheet" April 7, 1997, In Brief)
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.